Home Other Building Blocks 585543-15-3
585543-15-3,MFCD16619322
Catalog No.:AA00ECB6

585543-15-3 | Losmapimod

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$8.00   $6.00
- +
10mg
98%
in stock  
$25.00   $18.00
- +
25mg
98%
in stock  
$43.00   $30.00
- +
50mg
98%
in stock  
$67.00   $47.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00ECB6
Chemical Name:
Losmapimod
CAS Number:
585543-15-3
Molecular Formula:
C22H26FN3O2
Molecular Weight:
383.4591
MDL Number:
MFCD16619322
SMILES:
O=C(c1ccc(nc1)c1cc(cc(c1C)F)C(=O)NC1CC1)NCC(C)(C)C
Properties
Computed Properties
 
Complexity:
573  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
6  
XLogP3:
3.8  

Downstream Synthesis Route

[1]Locationinpatent:experimentalpartAston,NicolaM.;Bamborough,Paul;Buckton,JacquelineB.;Edwards,ChristopherD.;Holmes,DuncanS.;Jones,KatherineL.;Patel,VipulkumarK.;Smee,PennyA.;Somers,DonaldO.;Vitulli,Giovanni;Walker,AnnL.[JournalofMedicinalChemistry,2009,vol.52,#20,p.6257-6269]

[2]CurrentPatentAssignee:CSPCPHARMACEUTICALGROUPLIMITED-EP3357916,2018,A1Locationinpatent:Paragraph0101;0102

[3]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2005/14550,2005,A1Locationinpatent:Page/Pagecolumn37-38

[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2005/14550,2005,A1Locationinpatent:Page/Pagecolumn39

[1]CurrentPatentAssignee:CSPCPHARMACEUTICALGROUPLIMITED-EP3357916,2018,A1

[1]CurrentPatentAssignee:CSPCPHARMACEUTICALGROUPLIMITED-EP3357916,2018,A1

861905-94-4   
Losmapimod 

[1]CurrentPatentAssignee:CSPCPHARMACEUTICALGROUPLIMITED-EP3357916,2018,A1

Literature

Title: Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition.

Journal: Neurochemistry international 20151101

Title: Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Journal: JACC. Cardiovascular imaging 20120901

Title: An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.

Journal: Journal of clinical pharmacology 20120301

Title: Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.

Journal: Journal of medicinal chemistry 20111124

Title: Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.

Journal: Circulation 20110208

Title: Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

Journal: Journal of medicinal chemistry 20100325

Title: p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.

Journal: Journal of medicinal chemistry 20091022

Title: Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.

Journal: The Journal of pharmacology and experimental therapeutics 20090901

Title: Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330(3):964-70.

Title: Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 585543-15-3
Tags:585543-15-3 Molecular Formula|585543-15-3 MDL|585543-15-3 SMILES|585543-15-3 Losmapimod